| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/02/2005 | EP1501452A2 Injectable chondrocyte implant |
| 02/02/2005 | EP1436382A4 9136, a human aldehyde dehydrogenase family member and uses therefor |
| 02/02/2005 | EP1404334A4 Targeted delivery of bioaffecting compounds for the treatment of cancer |
| 02/02/2005 | EP1390365B1 Novel sulfonate substituted pyrazol pyridine dervivatives |
| 02/02/2005 | EP1351980A4 Peptides for activation and inhibition of delta pkc |
| 02/02/2005 | EP1292591B1 Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 02/02/2005 | EP1285269B1 Lipid uptake assays |
| 02/02/2005 | EP1259550B1 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| 02/02/2005 | EP1161235B1 Combinations for the treatment of diseases involving angiogenesis |
| 02/02/2005 | EP1135166B9 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 02/02/2005 | EP1092040B1 Methods of inhibiting helicobacter pylori |
| 02/02/2005 | EP1011688B1 Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases |
| 02/02/2005 | EP1007017B1 New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof |
| 02/02/2005 | CN1575338A Bv8 nucleic acids and polypeptides with mitogenic activity |
| 02/02/2005 | CN1575337A Mammalian receptor proteins; related reagents and methods |
| 02/02/2005 | CN1575191A Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors |
| 02/02/2005 | CN1575185A Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
| 02/02/2005 | CN1575184A Method and composition for treating immune complex associated disorders |
| 02/02/2005 | CN1575182A Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/02/2005 | CN1575181A Use of dinucleoside polyphosphate to stimulate removal of fluid in retinal disorders |
| 02/02/2005 | CN1575174A Pharmaceutically active isoindoline derivatives |
| 02/02/2005 | CN1575170A (-)-1-(3, 4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 02/02/2005 | CN1575169A Mch antagonists for the treatment of obesity |
| 02/02/2005 | CN1575168A Combinations comprising a selective cyclooxygenase-2 inhibitor |
| 02/02/2005 | CN1575165A Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole |
| 02/02/2005 | CN1575162A Combination dosage form containing a cholesterol -lowering agent , an inhibitor of the renin-angiotensin, and aspirin |
| 02/02/2005 | CN1575133A Process and composition for controlling fecal hair excretion and trichobezoar formation |
| 02/02/2005 | CN1572325A Treatment of lupus nephritis with anti-CD40L compounds |
| 02/02/2005 | CN1572318A Composition containing dipeptide of histidine and alanine for reducing uric acid |
| 02/02/2005 | CN1572303A Methods and compositions for the prevention of tolerance to medications |
| 02/02/2005 | CN1572299A Agents for improving excretory potency of urinary bladder |
| 02/02/2005 | CN1187370C Connective tissue growth factor fragments and methods and uses thereof |
| 02/02/2005 | CN1187084C Use of alpha1 & beta1 integrin receptor inhibitors and TGF-beta1 inhibitors in the treatment of kidney disease |
| 02/02/2005 | CN1187058C Stem cell medicine for repairing damage of central nerve and its preparing process |
| 02/02/2005 | CN1187056C Cyclo-oxygenase inhibitor and amidine derivative salts, preparation method thereof, use thereof as drugs, and pharmaceutical compositions containing said salts |
| 02/02/2005 | CN1187053C Uses of sugar cortexin receptor antagon for production of phrenopathic medicine |
| 02/02/2005 | CN1187052C Sustained release microsphere containing stavudine |
| 02/02/2005 | CN1187050C Endothelin antogonist and a renin-angiotensin system inhibitor as a combined preparation |
| 02/02/2005 | CN1187048C MGluR 5 antagonists for treatment of pain and anxiety |
| 02/02/2005 | CN1187044C Storable active substance concentrate containing formoterol |
| 02/02/2005 | CN1187035C Composition containing N-vinyl iminazole polymer or copolymer and oxidation sensitive hydrophilic active ingredients for cosmetics and/or dermatology |
| 02/01/2005 | US6849651 Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| 02/01/2005 | US6849631 Semicarbazides and their uses |
| 02/01/2005 | US6849630 Cyclized amino acid derivatives |
| 02/01/2005 | US6849617 Administering Tissue factor pathway inhibitors for prophylaxis of thrombosis and cardiovascular disorders; anticoagulants |
| 02/01/2005 | US6849613 Multiple antioxidant micronutrients |
| 02/01/2005 | US6849599 Combination drug therapy |
| 02/01/2005 | US6849598 A microbiocides, bactericides, fungicides, comprising a surfactant poloxamer, optionally with EDTA, for treating bacterial infections |
| 02/01/2005 | US6849436 Nucleotide sequences coding polypeptide for use in the treatment of blood disorders, gout, kidney stones, Lesch-Nyhan syndrome, renal failure and uricaciduria |
| 02/01/2005 | US6849421 Nucleotide sequences coding enzymatic polypeptide for the use in the treatment of nervous system disorders |
| 02/01/2005 | US6849420 Isolated autophosphorylating polypeptide, possessing PI3 kinase (phosphoinositide-3 kinase) activity; use drug screening for regulators of cell motility, such as antimetastasis agents |
| 02/01/2005 | US6849277 Composition for moist skin |
| 02/01/2005 | US6849269 Enteric-coated mixture of a poorly water soluble drug and a phospholipid |
| 02/01/2005 | US6849263 Pharmaceutical compositions for buccal delivery of pain relief medications |
| 02/01/2005 | US6849262 Vascular coating composition |
| 02/01/2005 | US6849261 CD4-independent HIV envelope proteins as vaccines and therapeutics |
| 02/01/2005 | US6849260 Methods and compositions for treating IgE-related disease using NNT-1 inhibitors |
| 02/01/2005 | CA2296080C Ophthalmic compositions containing galactomannan polymers and borate |
| 01/27/2005 | WO2005007849A1 Method of enhancing alkylating drug sensitivity |
| 01/27/2005 | WO2005007844A1 Method of screening for agents that modulate immunophilin/peptidylproline cis-trans isomerase (ppiase)-homer interaction |
| 01/27/2005 | WO2005007811A2 Injection of bone marrow-derived cells and medium for angiogenesis |
| 01/27/2005 | WO2005007328A1 Metal colloid solution |
| 01/27/2005 | WO2005007241A1 Parasiticidal composition |
| 01/27/2005 | WO2005007240A1 Combination treatment of neurological disorders comprising phospholipids |
| 01/27/2005 | WO2005007193A2 Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor |
| 01/27/2005 | WO2005007191A1 Medicinal composition |
| 01/27/2005 | WO2005007174A2 Synergistic antimicrobial ophthalmic combination |
| 01/27/2005 | WO2005007170A1 Method for treating irritable bowel syndrome using laxatives |
| 01/27/2005 | WO2005007166A1 Treatment of sexual dysfunction |
| 01/27/2005 | WO2005007156A1 Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin ii receptor antagonist for the treatment of central nervous system damage |
| 01/27/2005 | WO2005007155A1 Medicinal composition |
| 01/27/2005 | WO2005007153A1 A composition of amino acid-iodine complex and methods for preparing and application |
| 01/27/2005 | WO2005007149A1 Ambroxol for treating acute pains |
| 01/27/2005 | WO2005007148A1 Ambroxol for treating epilepsy |
| 01/27/2005 | WO2005007147A1 Ambroxol for treating tinnitus |
| 01/27/2005 | WO2005007146A1 Ambroxol for treating chronic nociceptive pains |
| 01/27/2005 | WO2005007140A1 Pharmaceutical composition containing insect repellent |
| 01/27/2005 | WO2005007086A2 A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 01/27/2005 | WO2005007082A2 Treatment of chronic bacterial infection |
| 01/27/2005 | WO2005006878A1 Compositions for improved oxidative status in companion animals |
| 01/27/2005 | WO2004085418A3 Xanthones, thioxanthones and acridinones as dna-pk inhibitors |
| 01/27/2005 | WO2004084927A3 Compositions for inducing of immunotolerance |
| 01/27/2005 | WO2004078178B1 Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use |
| 01/27/2005 | WO2004073623A9 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 01/27/2005 | WO2004062671A3 Pde4 inhibitors for the treatment of neoplasms of lymphoid cells |
| 01/27/2005 | WO2004060878A3 Inhibitors of phosphatases |
| 01/27/2005 | WO2003090687A3 Using heat shock proteins to increase immune response |
| 01/27/2005 | WO2003087374A9 Derivatives of the il-2 receptor gamma chain, their production and use. |
| 01/27/2005 | WO2003076565A3 Methods of using 46828, a human acyl-coa synthetase |
| 01/27/2005 | WO2002087554B1 Ef-tu binding agent as antibacterial agent |
| 01/27/2005 | US20050022256 Triple transgenic mouse model of alzheimer's disease |
| 01/27/2005 | US20050020695 Controlling ligands for regulating fertility and compounds for production of medicine from compounds |
| 01/27/2005 | US20050020690 Infiltration of capsaicin into surgical sites and open wounds |
| 01/27/2005 | US20050020686 Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
| 01/27/2005 | US20050020684 Modulators of peroxisome proliferator activated receptors |
| 01/27/2005 | US20050020671 Core comprises first active ingredient, coating comprising second active ingredient incompatible with first and barrier between core and coating which prevents physical contact between them, characterised in that barrier is formed on core by film-coating and coating is formed by press-coating |
| 01/27/2005 | US20050020668 Combination comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl] carbonyl]amino)phenyl] 2-methylpropanethioate and an HMG CoA reductase inhibitor |
| 01/27/2005 | US20050020665 For example, N-hydroxy-N-(1-benzo[b]thien-2-ylethyl) acetamide,1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxy urea,N-hydroxy-N-(1-benzo[b]thien-2-ylethyl)-N'-methyl urea |
| 01/27/2005 | US20050020657 Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2 |
| 01/27/2005 | US20050020656 L-histidine, D-histidine, DL-histidine, and/or salts thereof, and optionally cysteine, and/or cystine or salts; fibrosis may be of the kidney, pancreas, lung, vascular vessels, skin, bone marrow, or liver; may be given in foods or beverages |